Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity... Show more
Quantum Cyber N.V. is a Nasdaq-listed autonomous defense technology company building an artificial intelligence (AI)-powered, quantum-accelerated "system-of-systems" platform spanning drone warfare, counter-UAS (unmanned aerial systems), and border security. Formerly Mainz Biomed N.V., the company pivoted into defense technology in 2026, a repositioning that places it at the intersection of two high-visibility themes: AI-driven autonomy and quantum-enhanced navigation.
The company's competitive positioning rests on vertical integration rather than organic product development. By securing an exclusive license to an autonomous drone portfolio, acquiring a roughly 50,000-square-foot manufacturing facility in Bridgeport, Connecticut, and installing an 80-unit 3D-printing drone production line, management is attempting to control design, production, and cost structure under one entity. A Nevada-based subsidiary, Quantum Drones Corporation, is structured to help address foreign ownership, control, or influence (FOCI) rules that govern access to sensitive U.S. defense programs.
That said, the competitive moat remains unproven. The platform is assembled from licensed and acquired technologies, and the company's target of up to 100,000 drones in annual production is a forward-looking management projection, not current operational capacity. Rival incumbents and established primes have deeper engineering benches, classified-approval track records, and program-of-record relationships that a small-cap entrant must still earn.
The near-term trajectory hinges on whether strategic announcements convert into contracted, recurring revenue. The most consequential catalysts include:
The company's outlook is tightly coupled to U.S. defense budgets and doctrine. The proposed fiscal 2027 allocation — approximately $55 billion for drone and autonomous warfare — reflects a structural shift toward "attritable autonomy," the mass-produced, lower-cost systems validated in Ukraine, where inexpensive drones have neutralized far costlier armored platforms in electronic-warfare-saturated environments.
Policy tailwinds are concrete: an executive order establishing American drone dominance and "Buy American" procurement preferences favor domestic manufacturers, potentially giving the company's U.S. facility a tariff-advantaged position. The counter-UAS market is projected to grow from roughly $3.1 billion to $10.6 billion by 2030, a compound annual growth rate (CAGR) near 27%, according to third-party estimates cited by the company.
Offsetting these forces are interest-rate sensitivity for a capital-intensive, pre-revenue enterprise, export-control and FOCI compliance burdens, and long government procurement cycles that can stretch program awards over years. Geopolitically, the company is also courting Middle East and Gulf defense buyers, a channel that carries both opportunity and regulatory complexity.
The Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors monitoring early-stage defense names such as Quantum Cyber, the engine offers one data-driven lens for tracking emerging price behavior alongside fundamental catalysts.
Looking toward 2026 and beyond, the defining question is whether Quantum Cyber can move from a strategically assembled platform to a genuine defense manufacturer. Several structural themes will shape that transition:
Analyst expectations remain early and thinly sourced: a single $9 price target implies substantial upside from recent trading levels, but it reflects one firm's view rather than a broad consensus. As disclosures on contracts, revenue, and production capacity arrive, sentiment could shift rapidly in either direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QABA | 68.02 | 1.60 | +2.41% |
| First Trust NASDAQ ABA Community Bank Index Fund (QABA) | |||
| HDG | 53.53 | N/A | N/A |
| ProShares Hedge Replication ETF (HDG) | |||
| ATC | 19.19 | N/A | N/A |
| GraniteShares Autocallable COIN ETF (ATC) | |||
| MLRG | 104.20 | -0.47 | -0.45% |
| iShares MSCI USA ETF (MLRG) | |||
| CDX | 20.00 | -0.19 | -0.94% |
| Simplify High Yield ETF (CDX) | |||
A.I.dvisor indicates that over the last year, QUCY has been loosely correlated with ACRS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if QUCY jumps, then ACRS could also see price increases.
| Ticker / NAME | Correlation To QUCY | 1D Price Change % | ||
|---|---|---|---|---|
| QUCY | 100% | -9.61% | ||
| ACRS - QUCY | 41% Loosely correlated | -4.28% | ||
| STXS - QUCY | 27% Poorly correlated | +2.03% | ||
| ILMN - QUCY | 25% Poorly correlated | -3.99% | ||
| GH - QUCY | 24% Poorly correlated | -4.51% | ||
| ADVB - QUCY | 23% Poorly correlated | -11.30% | ||
More | ||||
Industry MedicalSpecialties
QUCY saw its Momentum Indicator move below the 0 level on October 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 109 similar instances where the indicator turned negative. In 100 of the 109 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QUCY turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 37 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
QUCY moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QUCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for QUCY entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for QUCY's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where QUCY advanced for three days, in 152 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
QUCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. QUCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.144) is normal, around the industry mean (65.876). P/E Ratio (-0.472) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. QUCY's P/S Ratio (60.976) is very high in comparison to the industry average of (9.775).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QUCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.